The Hypercalcaemic Syndrome in Rats Bearing the Walker Carcinosarcoma 256

Minne, H. W.; Raue, Friedhelm; Bellwinkel, S.; Ziegler, Reinhard

doi:10.1530/acta.0.0780613

Cited by 45 publications

(18 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cells from the hypercalcemic variant of Walker tumor were derived from explant cultures of the tumor that was kindly provided by Dr. R. Martodam of the Procter and Gamble Co., Cincinnatti, OH. All rats carrying these tumors subcutaneously developed hypercalcemia in the range of [13][14][15][16][17][18] mg/dl (10)(11)(12). Cells were grown in Dulbecco's modified Eagle medium supplemented with 10% (vol/vol) fetal calf serum (FCS), penicillin, 100 U/ml, and streptomycin, 100 ug/ml, and were incubated at 370C in a humidified 5% CO2, 95% air atmosphere.…”

Section: Methodsmentioning

confidence: 99%

Factors associated with humoral hypercalcemia of malignancy stimulate adenylate cyclase in osteoblastic cells.

Rodan¹,

Insogna²,

Vignery³

et al. 1983

J. Clin. Invest.

220

View full text Add to dashboard Cite

A B S T R A C T The culture media of three cell lines, a human prostate carcinoma (PC3), a rat Leydig cell tumor (Rice-500), and a rat carcinosarcoma , that were derived from tumors associated with humoral hypercalcemia of malignancy (HHM), were examined for stimulation of adenylate cyclase in ROS 17/2.8 osteoblastic cells and for bone resorptive activity in culture. Cells from a nonhypercalcemic variant of the WRC 256 tumor served as control. Extracts from three solid human tumors, a lung adenocarcinoma from a patient with HHM and two adendcarcinomata from normnocalcemic patients (lung and colon), were also examined for adenylate cyclase stimulation. We found excellent correlation between stimulation of cyclic AMP accumulation in ROS 17/2.8 cells and bone resorbing activity in culture, or production of HHM in vivo. Stimulation of adenylate cyclase by HHM factors was inhibited by the parathyroid hormone competitive inhibitor, [8norleucyl, '8norleucyl, 34tyrosinyl] bovine parathyroid hormone (3-34) amide.

show abstract

Section: Methodsmentioning

confidence: 99%

Factors associated with humoral hypercalcemia of malignancy stimulate adenylate cyclase in osteoblastic cells.

Rodan¹,

Insogna²,

Vignery³

et al. 1983

J. Clin. Invest.

220

View full text Add to dashboard Cite

show abstract

“…It reproduces, in part, human humoral hypercalcemia of malignancy (HHM) syndrome and, thus, it can be used as an experimental model of HHM [3]. The role of the kidney in the hyper calcemia associated to Walker-256-bearing rats has been studied and there is evidence for an altered tubular hand ling of calcium (an increase in tubular calcium reabsorp tion) [4], Serum 1,25-dihydroxyvitamin D (l,25(OH),D) levels are often depressed in the human HHM syndrome, however a small group of patients with solid tumors and hypercalcemia have increased 1,25(OH)2 levels [5,6], Con trary to the human HHM syndrome, serum levels of l,25(OH)2D are elevated in Walker 256 tumor-bearing rats [7,8].…”

Section: Introductionmentioning

confidence: 99%

Osseous and Intestinal Compartments in the Humoral Hypercalcemia of Malignancy Associated to Walker 256 Tumor in Rats

Torres¹,

Piedra²,

Rapado³

1993

Oncology

View full text Add to dashboard Cite

The objective of the present work has been to study some aspects of bone and intestinal compartments in rats with Walker 256 carcinosarcoma, an experimental model of humoral hypercalcemia of malignancy (HHM). The results have been compared to those obtained in control animals and, also, to those obtained in Yoshida sarcoma-bearing rats, which were used as tumoral controls without hypercalcemia. Urinary hydroxyproline/creatinine ratio (OHProl/creat) is increased, in both Walker 256 and Yoshida tumor-bearing animals, showing the nonspecifity of this bone marker. However, serum tar-trate-resistant acid phosphatase (TRAP) levels are increased in Walker 256 tumor-bearing animals, but they are normal in Yoshida tumor-bearing animals, indicating that TRAP is a better index of bone resorption than OHProl/ creat in the HHM syndrome. The decrease of bone calcium content in Walker 256 tumor-bearing rats, not shown by Yoshida-bearing rats, also reflects an increased bone resorption due to HHM. Serum and bone osteocalcin levels are similar in control, Walker 256 and Yoshida tumor-bearing rats, but we observed a decrease in serum alkaline phosphatase levels in Walker 256 and Yoshida tumor-bearing animals, which could also be a nonspecific tumor effect, due to the presence of the neoplasia. Our results support the convenience of the employment of a nonhypercalcemic tumor group as control in the HHM study, in addition to the healthy controls. We have also observed higher 1,25-dihydroxyvitamin D serum levels in Walker 256 tumor-bearing rats than in control and Yoshida tumor-bearing rats. On the other hand, we have found normal levels in the fractional rate of intestinal calcium absorption in Walker-256 tumor-bearing rats, in spite of their high calcium levels, and a significant decrease of this parameter in Yoshida sarcoma-bearing animals. These results support the concomitant contribution of intestinal compartment to hypercalcemia, in the experimental model of HHM studied.

show abstract

“…If this hypothesis is correct, then these PTH antagonists should inhibit the boneresorbing factors produced by these tumors, which are the primary cause of the hypercalcemia. To test the hypothesis, we examined two tumor models of HHM (5,6) which produced both bone-resorbing activity and factors which stimulate adenylate cyclase to determine if the bone-resorbing activity was mediated via PTH receptors.…”

Section: Introductionmentioning

confidence: 99%

Failure of parathyroid hormone antagonists to inhibit in vitro bone resorbing activity produced by two animal models of the humoral hypercalcemia of malignancy.

D'Souza¹,

Ibbotson²,

Mundy³

1984

J. Clin. Invest.

View full text Add to dashboard Cite

show abstract

The Hypercalcaemic Syndrome in Rats Bearing the Walker Carcinosarcoma 256

Cited by 45 publications

References 2 publications

Factors associated with humoral hypercalcemia of malignancy stimulate adenylate cyclase in osteoblastic cells.

Factors associated with humoral hypercalcemia of malignancy stimulate adenylate cyclase in osteoblastic cells.

Osseous and Intestinal Compartments in the Humoral Hypercalcemia of Malignancy Associated to Walker 256 Tumor in Rats

Failure of parathyroid hormone antagonists to inhibit in vitro bone resorbing activity produced by two animal models of the humoral hypercalcemia of malignancy.

Contact Info

Product

Resources

About